CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 204 enrolled
Drug / intervention
Anaferon +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03707912
NCT03707912Phase 4Completed
CompareCT.gov

Multicentre Double-blind Placebo-controlled Parallel Group Randomized Clinical Trial of Efficacy and Safety of Anaferon in the Treatment of Acute Respiratory Viral Infections

Materia Medica Holding·interventional·Posted Oct 16, 2018·Updated Sep 2, 2020

In Brief

A Phase 4 clinical trial evaluating Anaferon and Placebo for Acute Respiratory Viral Infections. Completed, enrolled 204 participants across 19 sites.

Detailed Summary

Purpose of the study: • To obtain additional data on the efficacy and safety of Anaferon in the treatment of acute respiratory viral infections.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcute Respiratory Viral Infections
CountriesRussia
Collaborators--

Timeline

Phase 4CompletedFinished
20192020202120222023202420252026
First PostedOct 16, 2018
Enrollment StartOct 9, 2018
Primary CompletionMar 15, 2019
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 7.7 years ago

Interventions

Anaferondrug

Oral administration.

Placebodrug

Oral administration.